BioSpace News Archive

Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s Investigational New Drug (IND) application to initiate the CHAPERONE study - the Company’s Phase III registration trial of MicroPine to reduce the progression of myopia in children.

Vizient, Inc., joins more than 50 other health care leaders in voicing its strong support for the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act.

Israel Parliament Approval is Expected to Catalyze Export of Medical Cannabis; ETCH Biotrace Solution Positioned as Safe and Secure Means to Manage the Legal Supply Chain for Export

Pathios Therapeutics (“Pathios”), an innovative biotech company focused on the development of first in class therapies for autoimmune diseases and immuno-oncology and Sygnature Discovery (“Sygnature”), jointly announce a strategic partnership to accelerate Pathios’ drug discovery and development programmes.

Research and development programs progressing well with clinical milestones expected in 2019 in our RSV, NASH, and HBV programs

The RSA Group, a leading Life Sciences executive search firm, announced today that Mark Johnson has joined the company as a Partner

Aflac Incorporated announced that it will present at the Bank of America Merrill Lynch 2019 Insurance Conference.

Rewind Therapeutics (“Rewind”), a private Belgian biotech company developing innovative first-in-class remyelinating therapies for myelin-related diseases, today announces the appointment of leading myelin and multiple sclerosis (“MS”) experts, Professors Robin Franklin and Catherine Lubetzki, to its Scientific Advisory Board.

SOMAVAC® Medical Solutions, Inc., a med tech company creating solutions to improve post-op care, announced today the appointment of Joelle Goan as Program Manager to aide in product development and commercial launch of its flagship device SOMAVAC® Sustained Vacuum Device.

AvalonBay Joins Leading Companies in Science-Based Targets Initiative